Fig. 8: Effects of anti-CD40 on the myeloid infiltrate of 4T1 tumor and tumor-draining lymph node. | Nature Communications

Fig. 8: Effects of anti-CD40 on the myeloid infiltrate of 4T1 tumor and tumor-draining lymph node.

From: Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors

Fig. 8

BALB/c mice implanted with 4T1 tumors were treated with the schedule in Fig. 6d. Tumor (left panels) and tumor-draining lymph node (tdLN) (right panels) were collected at day 17 for analysis of myeloid cells by flow cytometry. Dendritic cells (DCs) were defined as CD11b+ F4/80- CD11c+ cells among CD45+ cells (a, i), and DC1 were further defined by expression of XCR1 (b–f and j–n). Percentage of DC1 positive for CD40 (c, k) and mean fluorescence intensity (MFI) (d, l). Percentage of DC1 positive for CD80 (e) and CD86 (f) in tumor. Expression of CD80 (m) and CD86 (n) by DC1 in tdLN. Macrophages were defined as CD11b+ F4/80+ among CD45+ cells (g, h and o, p). M2-like macrophages were furher defined by expression of CD206. Treatment-related changes in their percentage in the tumor (h) and tdLN (p). Data are shown as mean ± SD, each dot represents one animal, n = 10 biologically independent mice/group. Populations were compared by Kruskal–Wallis and Dunn’s post-test for statistical significance. *, **, *** and **** indicate p-values < 0.05, 0.01, 0.001 and 0.0001 respectively. Source data and exact p values are provided in the Source Data file.

Back to article page